BioStock: Scandion Oncology strengthens executive leadership
As its clinical development program intensifies, Scandion Oncology can start planning for its next phase of the company development and clinical trials of its top candidate, SCO-101, in metastatic colorectal cancer. This means the company is ready to transition into its next phase of development, and it took a major step in that direction by appointing Bo Rode Hansen to the position of CEO. BioStock reached out to the new CEO to learn more about what’s in store for Scandion Oncology in the months to come.
Read the full interview with Bo Rode Hansen, CEO of Scandion Oncology, at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se
THERANEXUS : MINUTES OF THE COMBINED GENERAL MEETING OF 16 JUNE 2021
The general meeting adopted all the resolutions by a very large majority, with the exception of the 21st resolution concerning a delegation to increase the share capital in favor of employees who are members of a company savings plan, in accordance with the recommendation of the Board of Directors....
ADDvise Group AB (publ) to redeem its outstanding up to SEK 240,000,000 senior secured callable bonds with ISIN SE0010298166
Reference is further made to a call notice dated 21 May 2021, in which the Company informed the holders of the Bonds that it exercises its option to redeem all outstanding Bonds in full pursuant to Clause 8.3 (Voluntary total redemption (call option)) of the Terms and Conditions (the "Call Noti...
ADDvise Group AB (publ) begär inlösen av sitt utestående upp till 240 000 000 SEK seniora säkerställda obligationslån med ISIN SE0010298166
Hänvisning görs vidare till underrättelse daterad 21 maj 2021 i vilken Bolaget meddelade obligationsinnehavarna att man avser nyttja sin rätt till att återlösa samtliga utestående Obligationer i förtid i enlighet med punkt 8.3 (Voluntary total redemption (ca...